Home Page: Annals of Oncology

Published online: September 14, 2024 Annals of Oncology, the journal of the European Society for Medical Oncology and the Japanese Society of Medical Oncology, provides rapid and efficient peer-review publications on innovative cancer treatments or translational work related to oncology and precision medicine. ESMO Opens in new window is the European Society for Medical Oncology. Representing 40, 000 oncology professionals in 177 countries, ESMO is a reference for oncology education and information.

Read the full article here

Source: www.annalsofoncology.org

Categories: Oncologists1, General Medicine News

Tags: DYK,AnnalsofOncology

Tweets with this article

ESMO - Eur. Oncology

📖 ESMO invites you to mark @Annals_Oncology ’s 35th Anniversary by exploring significant milestones with the Milestones Monday series, the #DYK post series, exclusive interviews with Editors-in-Chief, and the 2023 most-cited papers of #AnnalsofOncology 🔗 https://t.co/svRapNh3do https://t.co/0ZzYQJNFsx

Related Articles

Combinatorial strategies targeting NEAT1 and AURKA as new potential therapeutic options for multiple myeloma

Multiple myeloma (MM) is a dreadful disease, marked by the uncontrolled proliferation of clonal plasma cells (PCs) within the bone marrow (BM). MM is characterized…

Haematologica December 26, 2024

IO-202 Plus Azacitidine Elicits Responses in HMA-Naive Chronic Myelomonocytic Leukemia

IO-202 plus azacitidine elicited an ORR of 66.7% in patients with HMA-naive chronic myelomonocytic leukemia.

OncLive.com December 26, 2024

Navtemadlin Reduces Spleen Size and Symptom Score in R/R Myelofibrosis

Navtemadlin monotherapy was safe and effective among patients with myelofibrosis who were relapsed or refractory to treatment with JAK inhibitors.

OncLive.com December 26, 2024

Dexamethasone-Sparing Regimen Improves Outcomes in Frail MM Patients

Daratumumab and lenalidomide improved survival outcomes over lenalidomide and dexamethasone in frail patients with newly diagnosed MM.

CancerTherapyAdvisor December 26, 2024

Call-for-Papers | JACC: CardioOncology

Submission Deadline: February 15, 2025 Cardio-oncology historically has focused on the cardiotoxic effects of cancer therapies; however, as our field continues to evolve, there is…

Oncology Advance December 26, 2024

Potential Biomarkers Positively Prognosticate Outcomes With Pembrolizumab Plus Chemo in High-Risk TNBC

Pembrolizumab plus chemotherapy conferred an efficacy advantage over chemotherapy alone in high-risk TNBC subgroups defined by potential biomarkers.

OncLive.com December 26, 2024

Arlo-cel Elicits 87% ORR in Heavily Pretreated, Relapsed/Refractory Multiple Myeloma

The GPRC5D-targeting CAR T-cell therapy arlocabtagene autoleucel also yielded a 53% complete response rate in relapsed/refractory multiple myeloma.

OncLive.com December 26, 2024

All-Oral Combo Yields High Response Rate in Relapsed/Refractory AML – Oncology Nurse Advisor

Revumenib, venetoclax, and ASTX727 (a fixed-dose combination of decitabine and cedazuridine) demonstrated efficacy in patients with relapsed or refractory AML.

OncologyNurseAdvisor December 26, 2024

Fixed-Duration Epcoritamab Is Active, Safe in Older Newly Diagnosed LBCL

Epcoritamab produced responses in older patients with newly diagnosed large B-cell lymphoma.

OncLive.com December 26, 2024

Brexu-Cel Provides Durable Responses in Relapsed/Refractory, BTK-Naive MCL

Brexu-cel led to an ORR of 91% in patients with relapsed/refractory MCL who were naive to BTK inhibitors, according to new data from the ZUMA-2…

OncLive.com December 26, 2024